Colorectal cancer (CRC) is a complex and multifactorial disease, in which genetic and environmental factors both seem to play a part. Many epidemiological studies have explored the association between genetic polymorphisms of X-ray repair cross-complementing group 3 (XRCC3) (Thr241Met) and Xeroderma pigmentosum group D (XPD) lysine to glutamine at codon 751 (Lys751Gln) and risk of CRC in various populations; however, the results are controversial. We conducted this case-control study in a West Algerian population to assess the potential role of this genetic polymorphism on the risk of CRC in this population. Genomic DNA was extracted from blood samples collected from 129 sporadic CRC patients and 148 normal controls. The polymorphisms were determined by pyrosequencing technique. The distribution of XRCC3 Thr241Met and XPD Lys751Gln genotypes among controls did not differ significantly from those predicted by the Hardy-Weinberg distribution (p > 0.05). There were no significant differences in the genotypes distribution and allele frequencies between CRC patients and controls. A significant association was found between the combined heterozygous of XRCC3 and homozygous variant of XPD gene and CRC. This is the first study on DNA repair genetic polymorphisms in West Algerian population, and it suggests that the XRCC3 Thr241Met and XPD Lys751Gln polymorphisms may not be associated with the CRC risk in this population.

No abstract

No abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. It in elderly people, with a median age at diagnosis of 70 years. The y is to explore whether G8 questionnaire may be helpful to decide the for older colorectal cancer patients.October 2015 to June 2017, we prospectively screened 137 !75-yearswith CRC who were referred for chemotherapy. In our center, underwent oncogeriatric screening for a comprehensive geriatric assessis positive in ! 85-years-old patients or 75-85-years-old patients with criteria: G8 scale,14, Pfeiffer test >2, Barthel index <90 and positive scale. In addition, age, comorbidity and ECOG performance status account for final treatment decision. We hypothesize G8 vulnerability with toxicity and may help guiding treatment decisions.age of screened patients was 80.44 years (75.1-88.9). The most frewas colon cancer (71.8%) followed by rectal cancer (28.2%). 47.4% of atic disease. G8 detected vulnerability (<14 score) in 62% of was more frequently dismissed in these fragile patients (45.9% ts vs 28.6 of G8!14 patients). Overall, 67 patients received chemother-70.1%, FOLFOX 19.4%, FOLFIRI 1.5%, clinical trial treatment 9%). for those patients who initiated treatment at full-dose intensity, a dose needed afterwards in 76% of G8<14 patients vs 28.6% of G8!14 patients e of chemotherapy also significantly differed, with any grade 3/4 50% vs 20% of patients respectively (p ¼ 0.041), and a higher risk ratio such toxicity for G8<14 patients (Risk ratio 4, 95% CI 0.995-16.074).tion of treatment due to toxicity was needed in 15.2% vs 6.7% of ly (p ¼ 0.43). There were no toxic deaths. <14 score correlates with a greater probability of presenting relevant n, G8 questionnaire identifies a group of patients who more likely n during treatment. For this reason, G8 appears to be a helpful for treatment decision-making in elderly colorectal cancer patients.SEER analysis of increasing disparities in age-related cause survival (CSS) among patients with colorectal cancer

Conclusion:The naïve indirect treatment comparison to state-of-the-art therapy indicated that P-32 microparticles combined with standard-of-care chemotherapy may provide significant and clinically relevant benefits for patients with unresectable LAPC and a valuable treatment option in an area of high unmet medical need.Legal entity responsible for the study: OncoSil Medical Ltd.